Kymera Therapeutics (NASDAQ:KYMR) Stock Rating Cut to “Sell” at Wall Street Zen

Kymera Therapeutics (NASDAQ:KYMR) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday, Wall Street Zen reports.

A number of other research analysts have also weighed in on KYMR. Oppenheimer reaffirmed an “outperform” rating and set a $140.00 price objective on shares of Kymera Therapeutics in a report on Thursday. Raymond James Financial reaffirmed an “outperform” rating on shares of Kymera Therapeutics in a report on Thursday. Citigroup lifted their price target on shares of Kymera Therapeutics from $135.00 to $150.00 and gave the company a “buy” rating in a research report on Monday, October 5th. Truist Financial reissued a “buy” rating and set a $150.00 price target (up from $136.00) on shares of Kymera Therapeutics in a research note on Friday. Finally, Barclays upped their price target on Kymera Therapeutics from $133.00 to $139.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $137.92.

Kymera Therapeutics Price Performance

Shares of KYMR opened at $126.63 on Friday. Kymera Therapeutics has a 1-year low of $55.66 and a 1-year high of $130.05. The stock has a market cap of $10.53 billion, a PE ratio of -34.98 and a beta of 1.98. The firm has a fifty day moving average price of $114.93 and a 200 day moving average price of $96.35.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Thursday, October 29th. The company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.26) by ($0.06). Kymera Therapeutics had a negative return on equity of 22.65% and a negative net margin of 285.33%. The firm had revenue of $1.35 million for the quarter, compared to analyst estimates of $3.28 million. During the same period last year, the firm earned ($0.94) EPS. The company’s quarterly revenue was up .0% on a year-over-year basis. As a group, equities analysts expect that Kymera Therapeutics will post -3.85 EPS for the current fiscal year.

Insider Activity

In other Kymera Therapeutics news, insider Brian Adams sold 6,371 shares of the firm’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $116.83, for a total transaction of $744,323.93. Following the completion of the transaction, the insider directly owned 50,254 shares in the company, valued at approximately $5,871,174.82. This trade represents a 11.25% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $113.80, for a total transaction of $3,414,000.00. Following the transaction, the chief executive officer owned 666,568 shares of the company’s stock, valued at approximately $75,855,438.40. The trade was a 4.31% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 15.98% of the company’s stock.

Hedge Funds Weigh In On Kymera Therapeutics

Several hedge funds have recently bought and sold shares of KYMR. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Kymera Therapeutics in the third quarter worth $514,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Kymera Therapeutics by 20.8% during the third quarter. China Universal Asset Management Co. Ltd. now owns 15,812 shares of the company’s stock valued at $1,747,000 after acquiring an additional 2,721 shares during the last quarter. Sterling Capital Management LLC boosted its stake in shares of Kymera Therapeutics by 378.6% during the third quarter. Sterling Capital Management LLC now owns 1,919 shares of the company’s stock valued at $215,000 after acquiring an additional 1,518 shares during the last quarter. Inspire Investing LLC acquired a new stake in shares of Kymera Therapeutics during the third quarter valued at $482,000. Finally, Nisa Investment Advisors LLC increased its position in Kymera Therapeutics by 45.9% during the 3rd quarter. Nisa Investment Advisors LLC now owns 2,073 shares of the company’s stock worth $232,000 after purchasing an additional 652 shares in the last quarter.

Key Stories Impacting Kymera Therapeutics

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Kymera reported positive Phase 1 results for KT-579, showing deep and sustained IRF5 degradation, strong modulation of disease-relevant biomarkers, and a favorable safety profile. The data support continued development of the company’s immunology pipeline. Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial
• Positive Sentiment: Truist Financial reaffirmed its “buy” rating and raised its price target from $136 to $150, implying further upside based on the current trading level. Truist Securities Adjusts Price Target on Kymera Therapeutics
• Positive Sentiment: BTIG Research raised its target from $134 to $139 and maintained a “buy” rating, adding to the favorable analyst sentiment.
• Neutral Sentiment: Kymera provided a Phase 1 update on the formulation study for KT-621, offering investors additional information on the program’s ongoing clinical development. KT-621 Formulation Study Update
• Neutral Sentiment: RBC increased its price target from $112 to $116 but retained a “sector perform” rating, signaling limited conviction at the current valuation.
• Negative Sentiment: Third-quarter results missed expectations: adjusted loss was $1.32 per share versus a $1.26 consensus loss, while revenue of $1.35 million was below the $3.28 million estimate. The net loss also widened year over year, highlighting ongoing cash-burn and execution risks. Kymera Therapeutics Q3 Net Loss Widens

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing medicines that selectively eliminate disease-causing proteins through targeted protein degradation. Its approach is designed to use the cell’s natural protein-disposal system to remove proteins that may be difficult to address with conventional drug modalities.

The company’s research and development programs have targeted a range of disease areas, including immune-mediated and inflammatory conditions, cancer, and other serious illnesses.